medical professional with patient with peripheral artery disease PAD
completed

The WAVE trial was a phase III international, multi-center RCT of warfarin plus antiplatelet therapy versus antiplatelet therapy alone in patients with peripheral arterial disease (PAD).

This was one of the largest trials to-date conducted in patients with PAD.

Co-primary endpoints:

  • Composite of CV death, MI, or stroke
  • Severe ischemia requiring reperfusion/reconstruction of the coronary or peripheral arterial circulation.

Secondary endpoints:

  • CV death, MI, stroke, amputation, revascularization of the coronary or peripheral arterial circulation
  • CV death, MI, stroke, amputation, revascularization and severe coronary ischemia with ECG changes
  • Death, MI, TIA, stroke, amputation, coronary or peripheral revascularization and severe coronary ischemia with ECG changes.

All primary and secondary endpoints were adjudicated.

Study Type

Interventional - Drug

Study Design

Randomized, open label, parallel group design.

NO. of Countries

7

NO. of Sites

80

NO. of Participants

2161

Study Period

2000-2006

Sponsor

PHRI

Back To Top